losartan has been researched along with Asymmetric Diabetic Proximal Motor Neuropathy in 3 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied the efficacy of losartan (50 mg once daily for 12 weeks) on albuminuria, peripheral and autonomic neuropathy in 25 normotensive microalbuminuric type 2 diabetics who were asymptomatic for neuropathy." | 9.10 | Effect of losartan on albuminuria, peripheral and autonomic neuropathy in normotensive microalbuminuric type 2 diabetics. ( Agarwal, SK; Anuradha, S; Babbar, R; Kubba, S; Prakash, A; Puri, V, 2003) |
| "We studied the efficacy of losartan (50 mg once daily for 12 weeks) on albuminuria, peripheral and autonomic neuropathy in 25 normotensive microalbuminuric type 2 diabetics who were asymptomatic for neuropathy." | 5.10 | Effect of losartan on albuminuria, peripheral and autonomic neuropathy in normotensive microalbuminuric type 2 diabetics. ( Agarwal, SK; Anuradha, S; Babbar, R; Kubba, S; Prakash, A; Puri, V, 2003) |
| "Angiotensin receptor blockers (ARBs; including candesartan, losartan, olmesartan and valsartan) are widely used to treat hypertension, heart failure and diabetic neuropathy." | 3.88 | Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study. ( Busby, J; Cardwell, CR; Hughes, C; Johnston, BT; McMenamin, Ú; Spence, A, 2018) |
| "Diabetes (particularly type 2 diabetes) represents a global health problem of epidemic proportions." | 2.43 | Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. ( Burnier, M; Zanchi, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Busby, J | 1 |
| McMenamin, Ú | 1 |
| Spence, A | 1 |
| Johnston, BT | 1 |
| Hughes, C | 1 |
| Cardwell, CR | 1 |
| Kubba, S | 1 |
| Agarwal, SK | 1 |
| Prakash, A | 1 |
| Puri, V | 1 |
| Babbar, R | 1 |
| Anuradha, S | 1 |
| Burnier, M | 1 |
| Zanchi, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Angiotensin Converting Enzyme Inhibitors & Angiotensin Receptor Blocker in the Treatment of Type 2 Diabetic Patients Adverse Drug Effects and Drug Interactions- a Survey in an Internal Medicine Department.[NCT00437775] | 300 participants | Observational | 2007-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for losartan and Asymmetric Diabetic Proximal Motor Neuropathy
| Article | Year |
|---|---|
Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compound | 2006 |
1 trial available for losartan and Asymmetric Diabetic Proximal Motor Neuropathy
| Article | Year |
|---|---|
Effect of losartan on albuminuria, peripheral and autonomic neuropathy in normotensive microalbuminuric type 2 diabetics.
Topics: Adult; Albuminuria; Antihypertensive Agents; Autonomic Nervous System Diseases; Diabetes Mellitus, T | 2003 |
1 other study available for losartan and Asymmetric Diabetic Proximal Motor Neuropathy
| Article | Year |
|---|---|
Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Biphen | 2018 |